Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 23208733)

1.

New approaches to the study of sepsis.

Ward PA.

EMBO Mol Med. 2012 Dec;4(12):1234-43. doi: 10.1002/emmm.201201375. Review.

2.

Role of C5 activation products in sepsis.

Ward PA.

ScientificWorldJournal. 2010 Dec 14;10:2395-402. doi: 10.1100/tsw.2010.216. Review.

3.

The role of complement, C5a and its receptors in sepsis and multiorgan dysfunction syndrome.

Flierl MA, Schreiber H, Huber-Lang MS.

J Invest Surg. 2006 Jul-Aug;19(4):255-65. Review.

PMID:
16835140
4.

The harmful role of c5a on innate immunity in sepsis.

Ward PA.

J Innate Immun. 2010;2(5):439-45. doi: 10.1159/000317194. Epub 2010 Jun 26. Review.

5.

[Pathophysiological basis of surgery-linked sepsis].

Vollmar B.

Chirurg. 2011 Mar;82(3):199-207. doi: 10.1007/s00104-010-2010-7. Review. German.

PMID:
21249327
6.

Role of complement in multiorgan failure.

Rittirsch D, Redl H, Huber-Lang M.

Clin Dev Immunol. 2012;2012:962927. doi: 10.1155/2012/962927. Epub 2012 Dec 20. Review.

7.

Immunosuppression in patients who die of sepsis and multiple organ failure.

Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD 2nd, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS.

JAMA. 2011 Dec 21;306(23):2594-605. doi: 10.1001/jama.2011.1829.

8.

The dark side of C5a in sepsis.

Ward PA.

Nat Rev Immunol. 2004 Feb;4(2):133-42. Review.

PMID:
15040586
9.

Controlling the complement system in inflammation.

Kirschfink M.

Immunopharmacology. 1997 Dec;38(1-2):51-62. Review.

PMID:
9476114
10.

New insights into cellular mechanisms during sepsis.

Hoesel LM, Gao H, Ward PA.

Immunol Res. 2006;34(2):133-41. Review.

PMID:
16760573
11.

Immunosuppression following surgical and traumatic injury.

Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M.

Surg Today. 2010 Sep;40(9):793-808. doi: 10.1007/s00595-010-4323-z. Epub 2010 Aug 26. Review.

PMID:
20740341
12.

Role of C5a-C5aR interaction in sepsis.

Guo RF, Riedemann NC, Ward PA.

Shock. 2004 Jan;21(1):1-7. Review.

PMID:
14676676
13.

In vivo biological responses in the presence or absence of C3.

Sarma JV, Ward PA.

Adv Exp Med Biol. 2007;598:240-50. Review. No abstract available.

PMID:
17892216
14.

A key role of C5a/C5aR activation for the development of sepsis.

Riedemann NC, Guo RF, Ward PA.

J Leukoc Biol. 2003 Dec;74(6):966-70. Epub 2003 Aug 1. Review.

15.

Role of C5a in multiorgan failure during sepsis.

Huber-Lang M, Sarma VJ, Lu KT, McGuire SR, Padgaonkar VA, Guo RF, Younkin EM, Kunkel RG, Ding J, Erickson R, Curnutte JT, Ward PA.

J Immunol. 2001 Jan 15;166(2):1193-9.

16.

Immunomodulatory therapy for sepsis: an update.

Christaki E, Anyfanti P, Opal SM.

Expert Rev Anti Infect Ther. 2011 Nov;9(11):1013-33. doi: 10.1586/eri.11.122. Review.

PMID:
22029521
17.

Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans.

Huber-Lang M, Sarma JV, Rittirsch D, Schreiber H, Weiss M, Flierl M, Younkin E, Schneider M, Suger-Wiedeck H, Gebhard F, McClintock SD, Neff T, Zetoune F, Bruckner U, Guo RF, Monk PN, Ward PA.

J Immunol. 2005 Jan 15;174(2):1104-10.

18.

Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.

Hotchkiss RS, Monneret G, Payen D.

Nat Rev Immunol. 2013 Dec;13(12):862-74. doi: 10.1038/nri3552. Epub 2013 Nov 15. Review.

19.

Protection of innate immunity by C5aR antagonist in septic mice.

Huber-Lang MS, Riedeman NC, Sarma JV, Younkin EM, McGuire SR, Laudes IJ, Lu KT, Guo RF, Neff TA, Padgaonkar VA, Lambris JD, Spruce L, Mastellos D, Zetoune FS, Ward PA.

FASEB J. 2002 Oct;16(12):1567-74.

20.

Surgical sepsis: dysregulation of immune function and therapeutic implications.

Boontham P, Chandran P, Rowlands B, Eremin O.

Surgeon. 2003 Aug;1(4):187-206. Review.

PMID:
15570763
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk